Ala Alenazi, PhD

Ala joined Kinnevik in 2024 and is an Investment Manager focused on venture and growth stage businesses within the life sciences and TechBio sectors across the U.S. and Europe.

Ala is passionate about the application of transformative technologies to reimagine the way we approach disease: from discovery to intervention and prevention. Her investment strategy centres on breakthrough companies that lead in the development of novel modalities and tech-driven infrastructures that enhance the drug discovery and development pipeline.

A trained Molecular Geneticist with a Ph.D from Cambridge University, her research background covered malaria intervention, ageing, and cancer.

Prior to Kinnevik, she led an EU-backed health accelerator based in the UK and Ireland and built a portfolio of early-stage techbio companies as a Principal in a UK-based seed fund.